Literature DB >> 11113052

Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.

J H Traverse1, Y J Chen, R Du, R J Bache.   

Abstract

BACKGROUND: Nitric oxide (NO) causes vasodilation by stimulation of guanylate cyclase in vascular smooth muscle to produce cGMP. The resultant vasodilator effect is regulated by a family of cGMP phosphodiesterases (PDEs). Sildenafil, a selective inhibitor of PDE5 used for treatment of erectile dysfunction, has been found to cause relaxation of isolated epicardial coronary artery segments. The present study examined the effects of sildenafil on coronary blood flow and hemodynamics during exercise in normal and ischemic heart. METHODS AND
RESULTS: In chronically instrumented normal dogs, sildenafil 2 mg/kg PO caused a slight but significant increase in left anterior descending (LAD) coronary blood flow during resting conditions, with a nonsignificant trend toward increased coronary flow during treadmill exercise. Exercise in the presence of LAD stenosis that decreased distal coronary pressure to 57+/-2 mm Hg reduced LAD flow during exercise from 69+/-8 to 41+/-7 mL/min (P:<0. 05), with hypoperfusion most severe in the subendocardium. At the same distal coronary pressure, sildenafil increased LAD flow in the ischemic region to 50+/-11 mL/min (P:<0.05). Increase in ischemic region blood flow produced by sildenafil was uniform across the LV wall, given that no change occurred in the transmural distribution of perfusion.
CONCLUSIONS: Inhibition of PDE5 with sildenafil caused vasodilation of coronary resistance vessels with an increase of blood flow into an ischemic myocardial region during exercise in the presence of coronary artery stenosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113052     DOI: 10.1161/01.cir.102.24.2997

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

Review 1.  Clinical update on sildenafil citrate.

Authors:  Ian H Osterloh; Alan Riley
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

Authors:  R Pofi; D Gianfrilli; R Badagliacca; C Di Dato; M A Venneri; E Giannetta
Journal:  J Endocrinol Invest       Date:  2015-07-05       Impact factor: 4.256

3.  Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das; Saisudha Koka; Ramzi A Ockaili; Lei Xi
Journal:  Exp Clin Cardiol       Date:  2011

4.  Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke.

Authors:  Lian Li; Quan Jiang; Li Zhang; Guangliang Ding; Zheng Gang Zhang; Qingjiang Li; James R Ewing; Mei Lu; Swayamprava Panda; Karyn A Ledbetter; Polly A Whitton; Michael Chopp
Journal:  Brain Res       Date:  2006-12-26       Impact factor: 3.252

5.  Sildenafil induces retinal vasodilatation in healthy subjects.

Authors:  Mona Pache; Peter Meyer; Christian Prünte; Selim Orgül; Ines Nuttli; Josef Flammer
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

6.  Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study.

Authors:  Scott J Denardo; Xuerong Wen; Eileen M Handberg; C Noel Bairey Merz; George S Sopko; Rhonda M Cooper-Dehoff; Carl J Pepine
Journal:  Clin Cardiol       Date:  2011-07-21       Impact factor: 2.882

Review 7.  Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

Authors:  Clint L Miller; Chen Yan
Journal:  J Cardiovasc Transl Res       Date:  2010-07-15       Impact factor: 4.132

Review 8.  Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review.

Authors:  Federico Marchini; Graziella Pompei; Emanuele D'Aniello; Andrea Marrone; Serena Caglioni; Simone Biscaglia; Gianluca Campo; Matteo Tebaldi
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-09       Impact factor: 3.727

Review 9.  Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Authors:  Yuan James Rao; Lei Xi
Journal:  Acta Pharmacol Sin       Date:  2008-12-08       Impact factor: 6.150

Review 10.  Treatment of coronary microvascular dysfunction.

Authors:  C Noel Bairey Merz; Carl J Pepine; Hiroki Shimokawa; Colin Berry
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.